Histiocytic Neoplasm
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (NCT05786924) | Institut de Recherches Internationales Servier | 2023-04-18 |
| Individual Patient Compassionate Use of Mirdametinib (NCT05028166) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany |
Track Histiocytic Neoplasm automatically
Every clearance here is in the API, with alerts when new ones post.